Related Experiment Video
Updated: Jun 12, 2026
06:37
Multispectral Real-time Fluorescence Imaging for Intraoperative Detection of the Sentinel Lymph Node in Gynecologic Oncology
Published on: October 20, 2010
Clinical fluorescent contrast agents for image-guided surgery.
Jingyao Wang1,2, Yu-Si Liao1, Jian-Xiao Liang1,2
1CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing 100190, China.
Fundamental Research
|June 11, 2026
Summary
Fluorescence image-guided surgery (FIGS) uses advanced contrast agents for better surgical precision. FDA-approved agents and emerging molecular probes enhance tumor visualization and patient outcomes.
Area of Science:
- Surgical Oncology
- Medical Imaging
- Pharmacology
Background:
- Fluorescence image-guided surgery (FIGS) enhances intraoperative visualization.
- Precision surgery demands contrast agents with improved specificity, safety, and efficacy.
- Regulatory approvals mark significant progress in FIGS contrast agents.
Purpose of the Study:
- To review FDA-approved intraoperative fluorescence contrast agents.
- To summarize emerging agents in clinical evaluation.
- To discuss agent selection criteria and future directions in precision surgery.
Main Methods:
- Comprehensive review of seven FDA-approved agents (ICG, Fluorescein Sodium, 5-ALA, MB, Cysview, Cytalux, Akalux).
- Analysis of molecular characteristics, indications, and clinical performance.
- Summary of emerging targeted molecular probes.
Main Results:
- FDA-approved agents include ICG, Fluorescein Sodium, 5-ALA, MB, Cysview, Cytalux, and Akalux.
- Emerging agents show a trend towards targeted molecular probes.
- Targeted agents improve tumor visualization, margin delineation, and detection of occult lesions, leading to better resections.
Conclusions:
- The evolution of contrast agents supports precision medicine in surgery.
- Appropriate agent selection depends on tissue specificity, administration, imaging depth, and regulatory status.
- Integration of molecular diagnostics and imaging will drive individualized surgical interventions and theranostics.
